New data suggest venetoclax may offset the negative prognostic impact of short telomeres in patients with chronic lymphocytic ...

In an interview, Paolo Ghia, MD, PhD, discussed updated data from the phase 2 CAPTIVATE trial of ibrutinib and venetoclax in ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic ...

Venetoclax combined with Roche’s Gazyva (obinutuzumab) is already in phase 1 development in previously untreated CLL, and in phase 2 as a monotherapy in first line CLL with a 17p13 deletion.

Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or window Visit us on TikTok. Opens in a new tab or window ...

plus venetoclax and obinutuzumab; the combination resulted in undetectable minimal residual disease in 81% of patients at one year. Pirtobrutinib was also the subject of the BRUIN CLL-321 trial ...

"Patients with treatment-naive CLL have several treatment options, including continuous BTK inhibitor therapy, fixed-duration venetoclax-based regimens, and chemoimmunotherapy, for low-risk ...

Here are the 5 most-viewed CLL/SLL pieces of 2024. 5. Real-World Study Confirms Efficacy of Venetoclax Alone, After BTKi Therapy in CLL According to this summary of findings shared at the 2023 ...

Suggested remit: To appraise the clinical and cost effectiveness of acalabrutinib and venetoclax with or without obinutuzumab within its marketing authorisation for previously untreated chronic ...